Iovance lifts 2026 revenue guidance to $410-420 millionSep 29FinancingaldesleukinIovance Biotherapeutics, Inc.
Iovance posts record Q2 2026 revenue, gains FDA fast track for lifileucel in sarcomasAug 6Quarterly updateIovance Biotherapeutics, Inc.lifileucel
Iovance registers two new trials: IOV-5001 solid tumor study and lifileucel sarcoma trialAug 4Weekly roundup, 2 itemsIOV-5001Iovance Biotherapeutics, Inc.
Iovance's cervical cancer TIL trial C-145-04 terminated after meeting event thresholdJul 31Trial updateIovance Biotherapeutics, Inc.lifileucel
FDA advisory committee backs RP1 efficacy data in advanced melanoma, 10-3Jul 30Regulatory milestoneReplimune, Inc.
Penn Medicine registers PICSTAT pilot testing CD8 PET imaging with Iovance's lifileucelJul 13Trial updateIovance Biotherapeutics, Inc.lifileucel
Sign inSign in